prazosin has been researched along with Neoplasms in 9 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment of benign prostatic hyperplasia (BPH) with nonselective alpha1 antagonists such as terazosin, doxazosin, and prazosin results in blood pressure reduction due to vasodilation." | 3.71 | Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. ( Chao, J; Chrischilles, E; Gilden, D; Kreder, KJ; Rubenstein, L; Shah, H, 2001) |
| "Presently cancer is a grave health issue with predominance beyond restrictions." | 2.72 | Therapeutic progression of quinazolines as targeted chemotherapeutic agents. ( Bansal, R; Malhotra, A, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Dolusić, E | 1 |
| Larrieu, P | 1 |
| Moineaux, L | 1 |
| Stroobant, V | 1 |
| Pilotte, L | 1 |
| Colau, D | 1 |
| Pochet, L | 1 |
| Van den Eynde, B | 1 |
| Masereel, B | 1 |
| Wouters, J | 1 |
| Frédérick, R | 1 |
| Bansal, R | 1 |
| Malhotra, A | 1 |
| Kozik, P | 1 |
| Gros, M | 1 |
| Itzhak, DN | 1 |
| Joannas, L | 1 |
| Heurtebise-Chrétien, S | 1 |
| Krawczyk, PA | 1 |
| Rodríguez-Silvestre, P | 1 |
| Alloatti, A | 1 |
| Magalhaes, JG | 1 |
| Del Nery, E | 1 |
| Borner, GHH | 1 |
| Amigorena, S | 1 |
| Fuchs, R | 2 |
| Stracke, A | 2 |
| Holzmann, V | 1 |
| Luschin-Ebengreuth, G | 1 |
| Meier-Allard, N | 1 |
| Ebner, N | 2 |
| Lassacher, TM | 1 |
| Absenger-Novak, M | 2 |
| Fröhlich, E | 1 |
| Schittmayer, M | 2 |
| Cano Crespo, S | 1 |
| Palacin, M | 1 |
| Rinner, B | 1 |
| Birner-Gruenberger, R | 2 |
| Zeller, CW | 1 |
| Raninger, AM | 1 |
| Kueznik, T | 1 |
| Friedman, GD | 1 |
| Udaltsova, N | 1 |
| Habel, LA | 1 |
| Robey, RW | 1 |
| Shukla, S | 1 |
| Finley, EM | 1 |
| Oldham, RK | 1 |
| Barnett, D | 1 |
| Ambudkar, SV | 1 |
| Fojo, T | 1 |
| Bates, SE | 1 |
| Riffkin, CD | 1 |
| Chung, R | 1 |
| Wall, DM | 1 |
| Zalcberg, JR | 1 |
| Cowman, AF | 1 |
| Foley, M | 1 |
| Tilley, L | 1 |
| Chrischilles, E | 1 |
| Rubenstein, L | 1 |
| Chao, J | 1 |
| Kreder, KJ | 1 |
| Gilden, D | 1 |
| Shah, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia[NCT03144596] | Phase 4 | 63 participants (Actual) | Interventional | 2015-10-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for prazosin and Neoplasms
| Article | Year |
|---|---|
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure; | 2021 |
1 trial available for prazosin and Neoplasms
| Article | Year |
|---|---|
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).
Topics: Adenosine Triphosphatases; Alkaloids; Animals; Antineoplastic Agents; ATP Binding Cassette Transport | 2008 |
7 other studies available for prazosin and Neoplasms
| Article | Year |
|---|---|
Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.
Topics: Animals; Antineoplastic Agents; Biological Availability; Cell Line; Drug Design; Enzyme Inhibitors; | 2011 |
Small Molecule Enhancers of Endosome-to-Cytosol Import Augment Anti-tumor Immunity.
Topics: Animals; Antigens; Antineoplastic Agents; beta-Lactamases; Biological Transport; Cross-Priming; Cyto | 2020 |
Prazosin induced lysosomal tubulation interferes with cytokinesis and the endocytic sorting of the tumour antigen CD98hc.
Topics: Cell Survival; Cytokinesis; Endocytosis; Fusion Regulatory Protein 1, Heavy Chain; Gene Expression R | 2018 |
The cytotoxicity of the α1-adrenoceptor antagonist prazosin is linked to an endocytotic mechanism equivalent to transport-P.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Apoptosis; Boron Compounds; Cell Pro | 2015 |
Norepinephrine antagonists and cancer risk.
Topics: Atenolol; Breast Neoplasms; Clonidine; Colonic Neoplasms; Female; Humans; Lung Neoplasms; Male; Meto | 2011 |
Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine.
Topics: Affinity Labels; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sit | 1996 |
Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study.
Topics: Accidental Falls; Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Cohort Studies; Comor | 2001 |